Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in HER2-Mutated Tumors (MATCH Subprotocol B)
NCT04439136Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in solid tumor, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Aug 2015; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439136.